Bitter pill for Cipla after bulk deal

Capital Market 

fell 0.94% to Rs 583 at 14:10 on after a bulk deal of 17.22 lakh was executed on the scrip at Rs 586.50 per share at 10:57 on

Meanwhile, the S&P Sensex was up 191.28 points, or 0.65%, to 29,767.02

Bulk deal boosted volume on the scrip. On the BSE, so far 18.68 lakh were traded in the counter, compared with average daily volumes of 1.48 lakh in the past one quarter. The stock had hit a high of Rs 591.75 and a low of Rs 581 so far during the day.

The stock hit a 52-week high of Rs 621.90 on 6 February 2017. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had underperformed the market over the past one month till 10 April 2017, rising 0.11% compared with 2.17% rise in the Sensex. The scrip also underperformed the market in past one quarter, rising 2.24% as against Sensex's 9.95% rise.

The large-cap pharmaceutical company has equity capital of Rs 160.90 crore. Face value per share is Rs 2.

Cipla's consolidated net profit rose 43.85% to Rs 374.83 crore on 15.64% rise in net sales to Rs 3550.02 crore in Q3 December 2016 over Q3 December 2015.

is a global pharmaceutical company. Its portfolio includes over 1000 products across wide range of therapeutic categories.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Bitter pill for Cipla after bulk deal

Cipla fell 0.94% to Rs 583 at 14:10 IST on BSE after a bulk deal of 17.22 lakh shares was executed on the scrip at Rs 586.50 per share at 10:57 IST on BSE.

fell 0.94% to Rs 583 at 14:10 on after a bulk deal of 17.22 lakh was executed on the scrip at Rs 586.50 per share at 10:57 on

Meanwhile, the S&P Sensex was up 191.28 points, or 0.65%, to 29,767.02

Bulk deal boosted volume on the scrip. On the BSE, so far 18.68 lakh were traded in the counter, compared with average daily volumes of 1.48 lakh in the past one quarter. The stock had hit a high of Rs 591.75 and a low of Rs 581 so far during the day.

The stock hit a 52-week high of Rs 621.90 on 6 February 2017. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had underperformed the market over the past one month till 10 April 2017, rising 0.11% compared with 2.17% rise in the Sensex. The scrip also underperformed the market in past one quarter, rising 2.24% as against Sensex's 9.95% rise.

The large-cap pharmaceutical company has equity capital of Rs 160.90 crore. Face value per share is Rs 2.

Cipla's consolidated net profit rose 43.85% to Rs 374.83 crore on 15.64% rise in net sales to Rs 3550.02 crore in Q3 December 2016 over Q3 December 2015.

is a global pharmaceutical company. Its portfolio includes over 1000 products across wide range of therapeutic categories.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22